Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.54 |
| ▸ | GHSR | Q92847 | 16/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL29233312 | 1.00 | ESR2 (0.54) | ESR2GHSRESR1 | |
| SCHEMBL7511979 | 0.90 | ESR2 (0.54) | ESR2GHSRESR1 | |
| SCHEMBL8224318 | 0.89 | GHSR (0.54) | ESR2GHSR | |
| SCHEMBL14863068 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL3056292 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL3075924 | 0.88 | ESR2 (0.52) | ESR2GHSRESR1 | |
| SCHEMBL25895785 | 0.88 | GHSR (0.48) | GHSR | |
| SCHEMBL15568922 | 0.87 | GHSR (0.52) | GHSR | |
| SCHEMBL1519350 | 0.86 | GHSR (0.59) | GHSR | |
| SCHEMBL2081445 | 0.85 | ESR2 (0.49) | ESR2GHSRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1951675-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | ESR2 1107/4885GHSR 1291/4885ESR1 3918/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | ESR2 248/4885GHSR 675/4885ESR1 656/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ESR2 248/4885GHSR 675/4885ESR1 656/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ESR2 248/4885GHSR 675/4885ESR1 656/4885 |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | ESR2 41/4885GHSR 351/4885ESR1 61/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | ESR2 1107/4885GHSR 1291/4885ESR1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.